Showing 921 - 940 results of 26,818 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 50 ((mg decrease) OR (nn decrease)) ))', query time: 0.67s Refine Results
  1. 921
  2. 922
  3. 923
  4. 924
  5. 925
  6. 926
  7. 927
  8. 928
  9. 929
  10. 930
  11. 931

    Image_1_IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt.TIF by Renée H. Fiechter (10230473)

    Published 2021
    “…</p><p>Objectives: To investigate the cellular and molecular pathways affected by IL-12p40/IL-23p40 blockade with ustekinumab in the synovium of PsA patients.</p><p>Methods: Eleven PsA patients with at least one inflamed knee or ankle joint were included in a 24-week single-center open-label study and received ustekinumab 45 mg/sc according to standard care at week 0, 4, and 16. …”
  12. 932

    Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates. by Xiaoyan Xia (560153)

    Published 2019
    “…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”
  13. 933
  14. 934
  15. 935
  16. 936
  17. 937
  18. 938

    Discovery of Novel Substituted <i>N</i>‑(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors by Jimin Xu (2208961)

    Published 2020
    “…Notably, among these derivatives, compound <b>15</b> showed improved anti-HAdV activity (IC<sub>50</sub> = 0.27 μM), significantly decreased cytotoxicity (CC<sub>50</sub> = 156.8 μM), and low <i>in vivo</i> toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further <i>in vivo</i> efficacy studies for the treatment of HAdV infections.…”
  19. 939
  20. 940